There’s been lots of attention on type 2 diabetes drugs recently, especially since they might also be able to support weight ...
Victoza); and the dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 tirzepatide (Mounjaro, Zepbound). “This was a safety-related labeling change for the glucagon-like peptide 1 receptor ...
The FDA became aware of the problem after a patient submitted a complaint to the regulator that a vial of semaglutide from Fullerton Wellness had an unidentified "black particulate" floating in it.
Wednesday’s update to the regulator’s drug shortage database is good news for Novo Nordisk, which has struggled to keep up ...
Both Ozempic and Mounjaro are approved by the FDA to treat Type 2 diabetes, but some doctors prescribe the medication ...
The millennial-skewed telehealth platform Hims & Hers (HIMS) announced Monday that it will start offering customers a generic version of liraglutide, an older GLP-1 weight loss drug, next year. The ...
Less than a month after the FDA removed Eli Lilly’s tirzepatide from its shortage list, the agency has done the same for Novo Nordisk’s rival GLP-1 semaglutide, potentially signaling the end of a d | ...
The end of the shortages for Mounjaro and Zepbound, both forms of tirzepatide, set off an industry-wide dispute from ...
Madrigal’s Rezdiffra has launched a new MASH market, but ‘tremendous change’ is on the horizon
With the FDA approval of the first specific drug for Metabolic Associated Steatohepatitis (MASH) in March this year, Madrigal’s Rezdiffra is a pioneer in a market set for rapid change. | With the FDA ...
It is a sign that Novo Nordisk’s efforts to ramp up the supply of those drugs are starting to pay off, as demand continues to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback